BiotechReality – Covering Industry, Business, and Academia
Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.
For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.
Bayer confirms the positive results of their Parkinson’s stem cell therapy initial trial developed by their subsidiary BlueRock Therapeutics. The trial was conducted on 12 patients which shows signs of reducing the Parkinson’s disease symptoms. Earlier, Bayer announced the success of the trial but the details were withheld. “Bayer AG […]
A SciRealityPress Associate
Contents in the website is licensed under CC BY-NC 4.0
Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio